Matinas BioPharma Holdings, Inc. Share Price & Technical Analysis
MTNB · $0.70 (+4.48%)
Healthcare / Biotechnology
$0.70
+4.48%
Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, identifies and develops pharmaceutical products using its lipid nanocrystal (LNC) platform technology. The company's LNC delivery technology platform utilizes lipid nanocrystals for the delivery of small molecules, nucleic acids, gene therapies, vaccines, proteins, and peptides. Its lead product candidate is MAT2203, an …
Price chart
Seasonality
May has 2 positive and 2 negative years (last 5 years shown)
0% return in May, -4% avg return in past 3 year May month.
-17% return in 2026, -46% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | 0% | 0% | -17% | 0% | 0% | – | – | – | – | – | – | – | -17% |
| 25 | 20% | 0% | -17% | 20% | 33% | 13% | 0% | 100% | 6% | -22% | -43% | -25% | 85% |
| 24 | -10% | 35% | -4% | -34% | -11% | -2% | 1% | -45% | -22% | -83% | 0% | -17% | -191% |
| 23 | 9% | -17% | -3% | 19% | -33% | -10% | 0% | -48% | -29% | 76% | -1% | 6% | -30% |
| 22 | -25% | -22% | 34% | -10% | 2% | 6% | 10% | -19% | -14% | 22% | -17% | -25% | -59% |
Monthly return % by calendar month · historical pattern, not a forecast
Weak · Downtrend · Strong
Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, identifies and develops pharmaceutical products using its lipid nanocrystal (LNC) platform technology. The company's LNC delivery technology platform utilizes lipid nanocrystals for the delivery of small molecules, nucleic acids, gene therapies, vaccines, proteins, and peptides. Its lead product candidate is MAT2203, an oral formulation of amphotericin B that is starting Phase 3 clinical trials for the treatment of aspergillosis and cryptococcosis, as well as prevention of invasive fungal infections in patients due to immunosuppressive therapy. It offers MAT2501, an orally administered formulation of amikacin. The company was incorporated in 2013 and is based in Bedminster, New Jersey.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$4.07M
P/E ratio
—
52W high
$3.09
52W low
$0.48
Volume
42,457
Beta
1.62
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is Matinas BioPharma Holdings, Inc. share price today?
- Matinas BioPharma Holdings, Inc. (MTNB) last traded around $0.70 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does MTNB have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for MTNB. Download the app for real-time alerts.
- How can I analyze Matinas BioPharma Holdings, Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.